ASCVDPhase 3ORION-8NCT03814187
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
A Phase 3 study testing Inclisiran Sodium in people with ASCVD and Elevated Cholesterol, run by Novartis Pharmaceuticals at 238 sites in 13 countries.
Trial summary
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia
- What is being tested?
- Inclisiran Sodium
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 3,275 participants
- Where
- 238 sitesin 13 countries
- Study dates
- 16 Apr 2019to 13 Feb 2023
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Completion on a previously qualifying inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3), or Phase III lipid lowering ORION feeder study [MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-4 (ORION-10), or MDCO-PCS-17-08 (ORION-11)] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol.
- On current lipid-lowering therapies (such as a statin and/or ezetimibe) from previous study with no planned medication or dose change during study participation.
- Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
Who cannot join
- Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk [according to investigator's (or delegate's) judgment] if he/she participates in the clinical study.
- An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
- Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 3 years,
- Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation >3x the upper limit of normal (ULN), or total bilirubin (TBIL) elevation >2x ULN at the last recorded visit in the feeder study prior to study entry visit.
- Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least one method of acceptable effective contraception (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
- Women >2 years postmenopausal (defined as 1 year or longer since last menstrual period) and more than 55 years of age.
Show all 16Show fewer
- Postmenopausal women (as defined above) and less than 55 years of age with a negative pregnancy test within 24 hours of randomization.
- Women who are surgically sterilized at least 3 months prior to enrollment.
- Planned use of other investigational medicinal products other than inclisiran or devices during the course of the study.
- Any condition that according to the investigator could interfere with the conduct of the study, such as but not limited to:
- Subjects who are unable to communicate or to cooperate with the investigator
- Unable to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study (including subjects whose cooperation is doubtful due to drug abuse or alcohol dependency)
- Unlikely to comply with the protocol requirements, instructions, and study-related restrictions (eg, uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study)
- Have any medical or surgical condition, which in the opinion of the investigator would put the subject at increased risk from participating in the study
- Persons directly involved in the conduct of the study.
- The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Trial locations and contacts
238 sites in 13 countries.
238 sites in 13 countries
United States141 sites
Research Site 10001-016
Akron, Ohio, 443311
Research Site 10001-054
Albany, New York, 12206
Research Site 10001-100
Amarillo, Texas, 79106
Research Site 10001-001
Anderson, South Carolina, 29621
Research Site 10001-059
Arlington Heights, Illinois, 60005
Research Site 10001-146
Athens, Tennessee, 37303
Research Site 10001-069
Atlanta, Georgia, 30342
Research Site 10001-087
Austin, Texas, 78726
Research Site 10001-117
Austin, Texas, 78756
Research Site 10001-073
Beverly Hills, California, 90211
Research Site 10001-122
Binghamton, New York, 13901
Research Site 10001-015
Birmingham, Alabama, 35211
Research Site 90001-047
Boca Raton, Florida, 33434
Research Site 90001-004
Boston, Massachusetts, 02114
Research Site 10001-060
Bridgewater, New Jersey, 08807
Research Site 90001-012
Butte, Montana, 59701
Research Site 10001-050
Canoga Park, California, 91303
Research Site 10001-011
Carlsbad, California, 92008
Research Site 10001-063
Cary, North Carolina, 27518
Research Site 10001-013
Chandler, Arizona, 85224
Research Site 10001-158
Chicago, Illinois, 60652
Research Site 10001-120
Cincinnati, Ohio, 45219
Research Site 90001-002
Cincinnati, Ohio, 45227
Research Site 10001-010
Cincinnati, Ohio, 45236
Research Site 10001-134
Cincinnati, Ohio, 45246
Research Site 10001-084
Clearwater, Florida, 33756
Research Site 10001-155
Clearwater, Florida, 33756
Research Site 10001-099
Clearwater, Florida, 33761
Research Site 10001-014
Columbus, Ohio, 43212
Research Site 10001-144
Crowley, Louisiana, 70526
Research Site 10001-009
Dallas, Texas, 75234
Research Site 10001-141
Dayton, Ohio, 45419
Research Site 10001-127
Daytona Beach, Florida, 32117
Research Site 10001-137
Dunwoody, Georgia, 30338
Research Site 10001-018
Edina, Minnesota, 55435
Research Site 10001-068
Edinburg, Texas, 78503
Research Site 10001-065
El Cajon, California, 92020
Research Site 10001-128
Endwell, New York, 13760
Research Site 10001-036
Evanston, Illinois, 60201
Research Site 10001-093
Falls Church, Virginia, 22042
Research Site 10001-119
Fleming Island, Florida, 32003
Research Site 10001-024
Flint, Michigan, 48504
Research Site 10001-138
Foley, Alabama, 36535
Research Site 10001-070
Fort Lauderdale, Florida, 33308
Research Site 10001-095
Grandville, Michigan, 49418
Research Site 10001-064
Greensboro, North Carolina, 27401
Research Site 10001-006
Greer, South Carolina, 29651
Research Site 10001-075.
Greer, South Carolina, 29651
Research Site 10001-067
Hialeah, Florida, 33012
Research Site 10001-031
Houston, Texas, 77002
Research Site 10001-088
Houston, Texas, 77024
Research Site 10001-091
Houston, Texas, 77027
Research Site 10001-061
Houston, Texas, 77058
Research Site 10001-032
Houston, Texas, 77070
Research Site 10001-113
Huntsville, Alabama, 35801
Research Site 10001-028
Hutchinson, Kansas, 67502
Research Site 10001-082
Indianapolis, Indiana, 46260
Research Site 10001-139
Jacksonville, Florida, 32204
Research Site 10001-039
Jacksonville, Florida, 32216
Research Site 10001-098
Jacksonville, Florida, 32216
Research Site 10001-130
Kingsport, Tennessee, 37660
Research Site 10001-118
Knoxville, Tennessee, 37909
Research Site 10001-106
Knoxville, Tennessee, 37917
Research Site 10001-041
Lake Charles, Louisiana, 70601
Research Site 90001-112
Las Vegas, Nevada, 89119
Research Site 10001-124
Las Vegas, Nevada, 89121
Research Site 10001-005
Layton, Utah, 84041
Research Site 10001-125
Lexington, Kentucky, 40503
Research Site 10001-108
Lexington, Kentucky, 40504
Research Site 10001-150
Los Angeles, California, 90022
Research Site 10001-092
Macon, Georgia, 31210
Research Site 10001-085
Manassas, Virginia, 20110
Research Site 10001-148
Marion, Ohio, 43302
Research Site 10001-077
Mesa, Arizona, 85213
Research Site 10001-081
Miami, Florida, 33126
Research Site 10001-140
Miami, Florida, 33126
Research Site 10001-142
Miami, Florida, 33126
Research Site 10001-030
Miami, Florida, 33165
Research Site 10001-116
Miami, Florida, 33183
Research Site 10001-080
Miami Springs, Florida, 33166
Research Site 10001-094
Midlothian, Virginia, 23114
Research Site 90001-005
Mission Viejo, California, 92691
Research Site 10001-058
Mobile, Alabama, 36608
Research Site 10001-101
Monroe, Louisiana, 71201
Research Site 10001-037
Montgomery, Alabama, 36117
Research Site 10001-145
Mooresville, North Carolina, 28117
Research Site 10001-111
Myrtle Beach, South Carolina, 29588
Research Site 10001-057
New Braunfels, Texas, 78130
Research Site 10001-042
New Windsor, New York, 12553
Research Site 10001-043
Northridge, California, 91324
Research Site 10001-022
Northridge, California, 91325
Research Site 10001-053
Omaha, Nebraska, 68134
Research Site 10001-021
Omaha, Nebraska, 68144
Research Site 10001-107
Owensboro, Kentucky, 42303
Research Site 10001-133
Pelzer, South Carolina, 29669
Research Site 10001-027
Pembroke Pines, Florida, 33024
Research Site 10001-115
Pembroke Pines, Florida, 33027
Research Site 10001-048
Pembroke Pines, Florida, 33029
Research Site 10001-147
Pembroke Pines, Florida, 33029
Research Site 10001-136
Phoenix, Arizona, 85014
Research Site 10001-003
Pinellas Park, Florida, 33781
Research Site 10001-104
Ponte Vedra, Florida, 32081
Research Site 10001-129
Poughkeepsie, New York, 12601
Research Site 10001-103
Rapid City, South Dakota, 57701
Research Site 10001-023
Richmond, Virginia, 23294
Research Site 10001-079
Round Rock, Texas, 78681
Research Site 10001-033
Sacramento, California, 95821-2134
Research Site 10001-090
Saint Augustine, Florida, 32086
Research Site 90001-056
Saint Paul, Minnesota, 55102
Research Site 10001-002
Salt Lake City, Utah, 84123
Research Site 10001-052
Salt Lake City, Utah, 94107
Research Site 10001-071
San Antonio, Texas, 78229
Research Site 10001-105
San Ramon, California, 94582
Research Site 10001-008
Santa Rosa, California, 95405
Research Site 10001-076
Saraland, Alabama, 36571
Research Site 10001-123
Sarasota, Florida, 34239-3513
Research Site 10001-083
Schertz, Texas, 78154
Research Site 10001-149
Shavano Park, Texas, 78231
Research Site 10001-046
Shelby, North Carolina, 28150
Research Site 10001-153
Spring Valley, California, 91978
Research Site 10001-156
St Louis, Missouri, 63136
Research Site 10001-007
St Louis, Missouri, 63141
Research Site 10001-102
St. Petersburg, Florida, 33713
Research Site 90001-015
Stanford, California, 94305
Research Site 10001-078
Sterling Heights, Michigan, 48310
Research Site 10001-029
Suffolk, Virginia, 23435
Research Site 90001-014
Summit, New Jersey, 07901
Research Site 10001-051
Surprise, Arizona, 85374
Research Site 10001-114
Tacoma, Washington, 98405
Research Site 10001-143
Tampa, Florida, 33614
Research Site 10001-045
Tomball, Texas, 77375
Research Site 10001-044
Torrance, California, 90502
Research Site 10001-034
Troy, Michigan, 48098
Research Site 10001-019
Tucson, Arizona, 85712
Research Site 10001-004
Tucson, Arizona, 85741
Research Site 10001-132
Tucson, Arizona, 85745
Research Site 10001-040
Valparaiso, Indiana, 46383
Research Site 10001-055
Warren Township, New Jersey, 07059
Research Site 10001-074
West Des Moines, Iowa, 50266
Research Site 10001-110
Williamsville, New York, 14221
Research Site 10001-109
Wyomissing, Pennsylvania, 19610
United Kingdom23 sites
Research Site 11044-028
Bollington, Cheshire, SK10 5JH
Research Site 11044-026
Bury
Research Site 11044-024
Cheadle Hulme
Research Site 11044-014
Chorley
Research Site 11044-012
Cornwell
Research Site 11044-010
Derby
Research Site 11044-006
Edgbaston
Research Site 11044-009
Exeter
Research Site 11044-001
Glasgow
Research Site 11044-008
Hexham
Research SIte 11044-020
Macclesfield
Research Site 11044-005
Manchester
Research Site 11044-025
Manchester
Research Site 11044-027
Manchester
Research Site 11044-029
Manchester
Research Site 11044-019
Plymouth
Research Site 11044-003
Reading
Research Site 11044-022
Sale
Research Site 11044-023
Sale
Research Site 11044-002
Stockton-on-Tees
Research Site 11044-021
Timperley
Research Site 11044-007
Wales
Research Site 11044-004
Waterloo
Poland18 sites
Research SIte 11048-016
Brzozowie
Research Site 11048-018
Bydgoszcz, 85-079
Research Site 11048-011
Bydgoszcz
Research Site 11048-004
Gdansk
Research Site 11048-005
Gdynia
Research Site 11048-007
Katowice
Research SIte 11048-012
Katowice
Research Site 11048-003
Krakow
Research SIte 11048-014
Krakow
Research Site 11048-008
Lublin
Research Site 11048-001
Poznan
Research Site 11048-019
Ruda Śląska, 41-709
Research SIte 11048-013
Rzeszów
Research SIte 11048-015
Tarnów
Research Site 11048-006
Warsaw
Research Site 11048-009
Warsaw
Research Site 11048-002
Wroclaw
Research Site 11048-010
Wroclaw
South Africa12 sites
Research Site 90027-008
Bellville, Cape Town, 7530
Research Site 90027-003
Bloemfontein, Free State, 9301
Research Site 90027-001
Cape Town, Western Cape, 7500
Research Site 90027-010
Johannesburg, Gauteng, 2193
Research Site 11027-005
Kempton Park, Gauteng, 1619
Research Site 11027-007
Kuils River, Western Cape, 7580
Research Site 90027-007
Lyttelton, Cape Town, 0157
Research Site 11027-013
Paarl, Western Cape, 7646
Research Site 90027-006
Pretoria, Gauteng, 0184
Research Site 90027-004
Somerset West, Western Cape, 7130
Research Site 90027-005
Somerset West, Western Cape, 7130
Research Site 90027-009
Witbank, Gauteng, 1035
Ukraine8 sites
Research Site 11380-005
Cherkasy
Research Site 11380-008
Kharkiv, 61176
Research Site 11380-001
Kyiv, 02002
Research Site 11380-002
Kyiv, 03037
Research Site 11380-003
Kyiv, 03049
Research Site 11380-004
Kyiv
Research Site 11380-006
Uzhhorod, 88000
Research Site 11380-009
Zaporizhzhya
Denmark6 sites
Research Site 90045-001
Aalborg, North Denmark, 9000
Research Site 90045-004
Esbjerg, 6700
Research Site 90045-003
Herning, 7400
Research Site 90045-006
Hvidovre, 2650
Research Site 90045-002
Roskilde, 4000
Research Site 90045-005
Viborg, 8800
Spain6 sites
Research Site 90034-003
A Coruña, Galicia, 15002
Research Site 90034-005
Barcelona, Catalonia, 08036
Research Site 90034-006
Barcelona, Catalonia, 08907
Research Site 90034-004
Córdoba, Andalusia, 14004
Research Site 90034-001
Reus, Catalonia, 43204
Research Site 90034-002
Zaragoza, Aragon, 5009
Germany5 sites
Research Site 11049-006
Berlin, 12627
Research Site 11049-002
Bochum, 47787
Research Site 11049-003
Frankfurt, 60313
Research Site 11049-001
Heidelberg, 69120
Research Site 11049-007
Heidelberg, 69120
Netherlands5 sites
Research Site 90031-001
Amersfoort, 3813 TZ
Research Site 90031-003
Amsterdam, 1105 AZ
Research Site 90031-006
Goes, 4462 RA
Research Site 90031-009
Hoorn, 1624 NP
Research Site 90031-005
Utrecht
Czechia4 sites
Research Site 11420-002
Chomutov, 430 02
Research Site 90420-001
Prague, 140 21
Research Site 90420-006
Prague, 180 81
Research Site 11420-003
Uherské Hradiště, 686 01
Hungary4 sites
Research Site 11036-001
Budapest
Research Site 11036-004
Debrecen
Research Site 11036-002
Hatvan
Research Site 11036-003
Zalaegerszeg
Canada3 sites
Research Site 90011-005
Chicoutimi, Quebec, G7H 7K9
Research Site 90011-001
Montreal, Quebec, H2W 1R7
Research Site 90011-002
Québec, Quebec, GIV 4W2
Sweden3 sites
Research Site 90046-002
Gothenburg, SE-41346
Research Site 90046-001
Stockholm, SE-11446
Research Site 90046-003
Stockholm, SE-14186
About this study
Official title: An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
Read the detailed description
This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800).
The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study.The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision.
In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study.
On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label.
On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080.
This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.
- Conditions
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
- Being tested
- Inclisiran Sodium
- Keywords
- Inclisiran sodium, ASCVD, LDL-C, HeFH, HoFH
- Medical subject headings
- Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Inclisiran SodiumDrug
Inclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis.
| Study group | Role | What they receive |
|---|---|---|
| Inclisiran | Experimental | Inclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990.
*Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90 Receives: Drug: Inclisiran Sodium |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk
The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS).
Target is <70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and <100 mg/dL for ASCVD risk equivalent subjects.
Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.
Measured: From ORION-8 Day 1 to the end of study (up to 1080 days)
Incidence of Treatment-emergent Adverse Events (TEAEs)
Safety assessments include adverse events and serious adverse events until the end of study.
End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.
Measured: From ORION-8 Day 1 to the end of study (up to 1080 days)
Secondary outcomes (4)
Absolute Change in LDL-C From the Initial Feeder Study Baseline
Absolute change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Measured: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change in LDL-C From the Initial Feeder Study Baseline
Percentage change from baseline in low density lipoprotein cholesterol (LDL-C) was calculated to evaluate the effect of inclisiran on LDL-C levels.
Measured: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Absolute change from baseline in total cholesterol, triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Measured: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Percentage change from baseline in total cholesterol (TC), triglycerides and high density lipoprotein cholesterol (HDL-C) was calculated to evaluate the effect of inclisiran on other lipids and lipoproteins.
Measured: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2019
- Study start16 Apr 2019
- Primary completion13 Feb 2023
- Study completion13 Feb 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for ASCVDStudies of the same condition, open and under way.
- More trials run by Novartis PharmaceuticalsThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 3,275 participants (actual)
Sponsor and investigators
- Lead sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Scott Wright, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03814187
- Sponsor's protocol ID
- MDCO-PCS-17-05
- Other IDs
- CKJX839A12306B, 2017-003092-55, 2017
- Acronym
- ORION-8
- Status last verified
- Feb 2024
- First submitted
- 17 Jan 2019
- Last updated
- 6 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Publications
Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
PubMed 38753448Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.
PubMed 33990512
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open-label Extension Trial of the Phase III Lipid-lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given as Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C
- ClinicalTrials.gov ID
- NCT03814187
- Acronym / sponsor ID
- ORION-8 / MDCO-PCS-17-05
- Conditions
- ASCVD, Elevated Cholesterol, Heterozygous Familial Hypercholesterolemia, Homozygous Familial Hypercholesterolemia
- Keywords
- Inclisiran sodium, ASCVD, LDL-C, HeFH, HoFH
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 3,275 participants (actual)
- Lead sponsor
- Novartis PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- 16 Apr 2019 (actual)
- Primary completion
- 13 Feb 2023 (actual)
- Study completion
- 13 Feb 2023 (actual)
- First posted
- 23 Jan 2019 (actual)
- Results
- Posted 6 Mar 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.
Detailed description
This study was an open label, long term extension study in subjects with atherosclerotic cardiovascular disease (ASCVD), ASCVD-risk equivalents (eg, diabetes and familial hypercholesterolemia), or heterozygous familial hypercholesterolemia (HeFH) and elevated low density lipoprotein cholesterol (LDL-C) despite maximum tolerated dose of LDL-C lowering therapies who have completed the inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3; NCT03060577), or any of the following Phase III lipid lowering studies: MDCO-PCS-17-03 (ORION-9; NCT03397121), MDCO-PCS-17-04 (ORION-10; NCT03399370), or MDCO-PCS-17-08 (ORION-11; NCT03400800).
The End of Study (EOS) visit in the previous feeder studies was Day 1 in this extension study.The duration that each subject participated in this study was a maximum of 3 years. However, for subjects from the Study ORION-3, the Sponsor decided to end the study prior to completion of their full 3-year of participation. It is recorded in the database as discontinuation was due to Sponsor's decision.
In this Phase III extension study, the same study drug of inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) was administered as a single subcutaneous (SC) dose every 180 days from the last dose in previous feeder study (except for subjects newly initiating inclisiran, who received the first two doses 90 days apart) until the end of the study.
On Day 1 (EOS visit in the feeder study), subjects from the previous feeder studies received blinded study medication except subjects from Study ORION-3. Subjects who received placebo in the previous Phase III feeder study received blinded inclisiran and subjects who received inclisiran in the previous feeder study received blinded placebo at this visit, so that subjects previously on placebo received the correct dosing regime, i.e. a dose at Day 1, Day 90 and every 180-days thereafter. Subjects previously treated with inclisiran did not need a dose of inclisiran to maintain every 180-dosing regime and therefore, were given placebo in order to maintain the blinding of the feeder study. Subjects that moved over from ORION-3 received the first study medication at Day 90, as this study was already open-label.
On Day 90, all subjects received inclisiran sodium 300 mg. This is 180 days after the last injection in the previous feeder study for subjects that received inclisiran and was the second dose of inclisiran for the subjects that received placebo in the feeder study. The EOS visit occurred at Day 1080.
This extension study allowed subjects continued access to inclisiran treatment and allowed the collection of additional efficacy and safety data for long-term use beyond the end of the feeder studies.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Inclisiran | Experimental | Drug: Inclisiran SodiumInclisiran sodium 300 milligrams (mg) was administered as a single SC injection on Day 1*, 90, then every 180 days to Day 990. *Subjects who received blinded placebo in the feeder study received blinded inclisiran and subjects who received blinded inclisiran in the feeder study received blinded placebo on Day 1 in ORION-8. Subjects from the open label ORION-3 study did not receive any injection of study drug on Day 1. Their first dose of study medication was at day 90 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Completion on a previously qualifying inclisiran Phase II trial MDCO-PCS-16-01 (ORION-3), or Phase III lipid lowering ORION feeder study [MDCO-PCS-17-03 (ORION-9), MDCO-PCS-17-4 (ORION-10), or MDCO-PCS-17-08 (ORION-11)] meaning the subject received the last dose of study drug and completed the final study visit per applicable protocol.
- On current lipid-lowering therapies (such as a statin and/or ezetimibe) from previous study with no planned medication or dose change during study participation.
- Willing and able to give informed consent before initiation of any study-related procedures and willing to comply with all required study procedures.
Key exclusion criteria (16 listed)
- Any uncontrolled or serious disease, or any medical or surgical condition, that may either interfere with participation in the clinical study, and/or put the subject at significant risk [according to investigator's (or delegate's) judgment] if he/she participates in the clinical study.
- An underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results.
- Severe concomitant noncardiovascular disease that carries the risk of reducing life expectancy to less than 3 years,
- Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver or unexplained alanine aminotransferase (ALT), aspartate aminotransferase (AST), elevation >3x the upper limit of normal (ULN), or total bilirubin (TBIL) elevation >2x ULN at the last recorded visit in the feeder study prior to study entry visit.
- Females who are pregnant or nursing, or who are of childbearing potential and unwilling to use at least one method of acceptable effective contraception (eg, oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device) for the entire duration of the study. Exemptions from this criterion:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Inclisiran SodiumInclisiran is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis. | Drug | Inclisiran |
Primary outcome
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
The primary objective of the study is to evaluate the effect of inclisiran treatment on the proportion of subjects achieving prespecified LDL-C targets at end of study (EOS). Target is <70 mg/dL for atherosclerotic cardiovascular disease (ASCVD) subjects and <100 mg/dL for ASCVD risk equivalent subjects. Risk equivalent subjects are defined as either type 2 diabetes, familial hypercholesterolemia or a 10-year risk of a cardiovascular event ≥20% as assessed by the Framingham Risk Score or equivalent; without a medical history of coronary heart disease , cerebrovascular disease or peripheral artery disease.
Incidence of Treatment-emergent Adverse Events (TEAEs)
Time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)
Safety assessments include adverse events and serious adverse events until the end of study. End of study visit occured at least 90 days following the last inclisiran dose once a decision was made to end the study (either by the subject, investigator or sponsor). For subjects prematurely and permanently discontinued from study treatment, who were not willing to return within the 90 day timeframe, the EOS visit was scheduled as soon as possible, or if decision to discontinue and not return was made at a specific visit, this visit became the EOS visit.
4 secondary outcomes
Absolute Change in LDL-C From the Initial Feeder Study Baseline
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change in LDL-C From the Initial Feeder Study Baseline
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Absolute Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Percentage Change From the Initial Feeder Study Baseline in Total Cholesterol, Triglycerides and HDL-C
Time frame: Feeder study baseline, ORION-8 baseline, Day 1080/EOS (ORION-8) (up to a maximum of 2340 days)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 38753448Wright RS, Raal FJ, Koenig W, Landmesser U, Leiter LA, Vikarunnessa S, Lesogor A, Maheux P, Talloczy Z, Zang X, Schwartz GG, Ray KK. Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial. Cardiovasc Res. 2024 Oct 14;120(12):1400-1410. doi: 10.1093/cvr/cvae109.
- Derived from this study: PubMed 33990512Warden BA, Duell PB. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins. J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.
- Individual participant dataSharing planned: Yes. Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Related trials for ASCVD
Active, not recruitingObservational study
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
Primary Hypercholesterolemia, Mixed Dyslipidemia
Not yet recruiting
Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD)
Coronary Artery Disease, Atherosclerotic Cardiovascular Disease (ASCVD)
RecruitingPhase 2
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
Atherosclerosis, Cardiovascular Disease
RecruitingObservational study
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Testicular Cancer, Survivorship
Active, not recruitingPhase 2
Phase 2 Study of Kylo-11 in ASCVD Patients With Elevated Lp(a)
Lipoprotein Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Scott Wright, MD principal investigator
Mayo Clinic
238 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Inclisiran Sodium in people with ASCVD and Elevated Cholesterol, run by Novartis Pharmaceuticals at 238 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 238 sites in United States, United Kingdom, Poland, South Africa, Ukraine and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 6 Mar 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Subjects Achieving Global Lipid Targets for Their Level of ASCVD Risk (time frame: From ORION-8 Day 1 to the end of study (up to 1080 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03814187, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2024.